

SENATE BILL No. 52

DIGEST OF SB 52 (Updated January 23, 2018 1:13 pm - DI 106)

Citations Affected: IC 4-13; IC 16-18; IC 16-42; IC 24-4; IC 35-31.5; IC 35-48.

Synopsis: Zero THC hemp extract. Repeals all provisions concerning the cannabidiol registry and a "substance containing cannabidiol" (all added by HEA 1148-2017). Defines "zero THC hemp extract" as a product derived from Cannabis sativa L. that contains not more than 0.3% THC and no other controlled substances. Establishes requirements for the manufacture and sale of zero THC hemp extract. Makes conforming amendments.

Effective: July 1, 2018.

Young M, Stoops

January 3, 2018, read first time and referred to Committee on Rules and Legislative

Procedure.

January 11, 2018, amended; reassigned to Committee on Corrections and Criminal Law.
January 25, 2018, amended, reported favorably — Do Pass.



Second Regular Session 120th General Assembly (2018)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2017 Regular Session of the General Assembly.

SENATE BILL No. 52

A BILL FOR AN ACT to amend the Indiana Code concerning criminal law and procedure.

Be it enacted by the General Assembly of the State of Indiana:

1	SECTION 1. IC 4-13-18-6, AS ADDED BY P.L.160-2006,
2	SECTION 2, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3	JULY 1, 2018]: Sec. 6. (a) A contractor's employee drug testing
4	program must satisfy all of the following:
5	(1) Each of the contractor's employees must be subject to a drug
6	test at least one (1) time each year.
7	(2) Subject to subdivision (1), the contractor's employees must be
8	tested randomly. At least two percent (2%) of the contractor's
9	employees must be randomly selected each month for testing.
0	(3) The program must contain at least a five (5) drug panel that
l 1	tests for the following:
12	(A) Amphetamines.
13	(B) Cocaine.
14	(C) Opiates (2000 ng/ml).
15	(D) PCP.
16	(E) THC.
17	(4) The program must impose progressive discipline on an



1	employee who fails a drug test. The discipline must have at least
2	the following progression:
3	(A) After the first positive test, an employee must be:
4	(i) suspended from work for thirty (30) days;
5	(ii) directed to a program of treatment or rehabilitation; and
6	(iii) subject to unannounced drug testing for one (1) year,
7	beginning the day the employee returns to work.
8	(B) After a second positive test, an employee must be:
9	(i) suspended from work for ninety (90) days;
10	(ii) directed to a program of treatment or rehabilitation; and
11	(iii) subject to unannounced drug testing for one (1) year,
12	beginning the day the employee returns to work.
13	(C) After a third or subsequent positive test, an employee must
14	be:
15	(i) suspended from work for one (1) year;
16	(ii) directed to a program of treatment or rehabilitation; and
17	(iii) subject to unannounced drug testing for one (1) year,
18	beginning the day the employee returns to work.
19	The program may require dismissal of the employee after any
20	positive drug test or other discipline more severe than is described
21	in this subdivision.
22	(b) An employer complies with the requirement of subsection (a) to
23	direct an employee to a program of treatment or rehabilitation if the
24	employer does either of the following:
25	(1) Advises the employee of any program of treatment or
26	rehabilitation covered by insurance provided by the employer.
27	(2) If the employer does not provide insurance that covers drug
28	treatment or rehabilitation programs, the employer advises the
29	employee of agencies known to the employer that provide drug
30	treatment or rehabilitation programs.
31	(c) A positive result on a drug test due solely to an employee's
32	use of zero THC hemp extract (as defined in IC 35-48-1-28) is not
33	considered a positive test for purposes of this section.
34	SECTION 2. IC 16-18-2-45.5 IS REPEALED [EFFECTIVE JULY
35	1, 2018]. Sec. 45.5. "Cannabidiol", for purposes of IC 16-42-28.6, has
36	the meaning set forth in IC 16-42-28.6-1.
37	SECTION 3. IC 16-18-2-48.7 IS REPEALED [EFFECTIVE JULY
38	1, 2018]. Sec. 48.7. "Caregiver", for purposes of IC 16-42-28.6, has the
39	meaning set forth in IC 16-42-28.6-2.
40	SECTION 4. IC 16-18-2-272, AS AMENDED BY P.L.188-2017,
41	SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
42	JULY 1, 2018]: Sec. 272. (a) "Patient", for purposes of IC 16-27-1, has



1	the meaning set forth in IC 16-27-1-6.
2	(b) "Patient", for purposes of IC 16-28 and IC 16-29, means ar
3	individual who has been accepted and assured care by a health facility
4	(c) "Patient", for purposes of IC 16-36-1.5, has the meaning set forth
5	in IC 16-36-1.5-3.
6	(d) "Patient", for purposes of IC 16-39, means an individual who has
7	received health care services from a provider for the examination
8	treatment, diagnosis, or prevention of a physical or mental condition
9	(e) "Patient", for purposes of IC 16-42-28.6, has the meaning se
10	forth in IC 16-42-28.6-3.
11	SECTION 5. IC 16-18-2-282, AS AMENDED BY P.L.188-2017
12	SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
13	JULY 1, 2018]: Sec. 282. (a) "Physician", except as provided in
14	subsections (b) and (c), through (d), means a licensed physician (as
15	defined in section 202 of this chapter).
16	(b) "Physician", for purposes of IC 16-41-12, has the meaning se
17	forth in IC 16-41-12-7.
18	(c) "Physician", for purposes of IC 16-37-1-3.1 and IC 16-37-3-5
19	means an individual who:
20	(1) was the physician last in attendance (as defined in section
21	282.2 of this chapter); or
22	(2) is licensed under IC 25-22.5.
23	(d) "Physician", for purposes of IC 16-42-28.6, has the meaning se
24	forth in IC 16-42-28.6-4.
25	(e) (d) "Physician", for purposes of IC 16-48-1, is subject to
26	IC 16-48-1-2.
27	SECTION 6. IC 16-18-2-342.6 IS REPEALED [EFFECTIVE JULY
28	1,2018]. Sec. 342.6. "Substance containing cannabidiol", for purposes
29	of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-5.
30	SECTION 7. IC 16-18-2-354.7 IS REPEALED [EFFECTIVE JULY
31	1, 2018]. Sec. 354.7. "Treatment resistant epilepsy", for purposes of
32	IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-6.
33	SECTION 8. IC 16-42-28.6 IS REPEALED [EFFECTIVE JULY 1
34	2018]. (Drugs: Use of Cannabidiol for the Treatment of Epilepsy).
35	SECTION 9. IC 24-4-21 IS ADDED TO THE INDIANA CODE AS
36	A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY
37	1, 2018]:
38	Chapter 21. Zero THC Hemp Extract Production
39	Sec. 1. The following definitions apply throughout this chapter
40	(1) "Certificate of analysis" means a certificate from an
41	independent testing laboratory describing the results of the
42	laboratory's testing of a sample.



1	(2) !!!!
1	(2) "Independent testing laboratory" means a laboratory:
2	(A) with respect to which no person having a direct or
3	indirect interest in the laboratory also has a direct or
4	indirect interest in a facility that:
5	(i) processes, distributes, or sells zero THC hemp
6	extract;
7	(ii) processes, distributes, or sells a substance containing
8	cannabidiol (as defined in IC 35-48-1-26.7), or a
9	substantially similar substance in another jurisdiction;
10	(iii) cultivates, processes, distributes, dispenses, or sells
11	marijuana; or
12	(iv) cultivates, processes, or distributes industrial hemp
13	and
14	(B) that is accredited as a testing laboratory to
15	International Organization for Standardization (ISO)
16	17025 by a third party accrediting body such as the
17	American Association for Laboratory Accreditation
18	(A2LA) or Assured Calibration and Laboratory
19	Accreditation Select Services (ACLASS).
20	(3) "Zero THC hemp extract" has the meaning set forth in
21	IC 35-48-1-28.
22	Sec. 2. A person may:
23	(1) manufacture zero THC hemp extract for distribution in
24	Indiana; and
25	(2) distribute zero THC hemp extract to a retailer or
26	independent testing laboratory in Indiana;
27	if the person meets the requirements of this chapter.
28	Sec. 3. A manufacturer shall submit a random sample of each
29	batch of product to an independent testing laboratory for testing
30	before the batch may be distributed. The manufacturer shall select
31	and submit the sample in a manner determined by the independent
32	testing laboratory. A manufacturer may not distribute a batch
33	until the manufacturer has obtained a certificate of analysis from
34	the independent testing laboratory showing that the sample
35	contains no tetrahydrocannabinol.
36	Sec. 4. If testing by the independent testing laboratory
37	demonstrates that a sample contains tetrahydrocannabinol, the
38	manufacturer:
39	(1) may not distribute the batch; and
40	(2) may reprocess the batch to remove the
41	tetrahydrocannabinol.
4.1	ten any di ocannavinoi.

A manufacturer shall treat a reprocessed batch as a new batch for



42

1	all purposes, and shall submit a new sample from the batch to the
2	independent testing laboratory for testing in accordance with
3	section 3 of this chapter.
4	Sec. 5. After receiving a certificate of analysis showing that the
5	product contains no tetrahydrocannabinol, the manufacturer shall
6	package the zero THC hemp extract in packaging that contains the
7	following information:
8	(1) A scannable bar code or QR code linked to a document
9	that contains information with respect to the manufacture of
10	the zero THC hemp extract, including the:
11	(A) batch identification number;
12	(B) product name;
13	(C) batch date;
14	(D) expiration date, which must be not more than two (2)
15	years from the date of manufacture;
16	(E) batch size;
17	(F) total quantity produced;
18	(G) ingredients used, including the:
19	(i) ingredient name;
20	(ii) name of the company that manufactured the
21	ingredient;
22	(iii) company or product identification number or code
23	if applicable; and
24	(iv) ingredient lot number; and
25	(H) download link for a certificate of analysis for the zero
26	THC hemp extract.
27	(2) The batch number.
28	(3) The Internet address of a web site to obtain batch
29	information.
30	(4) The expiration date.
31	(5) The number of milligrams of zero THC hemp extract.
32	(6) The manufacturer.
33	(7) The fact that the product contains no
34	tetrahydrocannabinol.
35	Sec. 6. A person who violates sections 3 through 5 of this chapter
36	commits a Class B infraction. However, the offense is a Class A
37	infraction if the person has a prior unrelated judgment for a
38	violation of this chapter.
39	SECTION 10. IC 24-4-22 IS ADDED TO THE INDIANA CODE
40	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
41	JULY 1, 2018]:
42	Chapter 22. Zero THC Hemp Extract Sales



1	Sec. 1. The following definitions apply throughout this chapter:
2	(1) "Certificate of analysis" has the meaning set forth in
3	IC 24-4-21-1.
4	(2) "Zero THC hemp extract" has the meaning set forth in
5	IC 35-48-1-28.
6	Sec. 2. A person may sell zero THC hemp extract at retail if the
7	packaging complies with the requirements of IC 24-4-21-5.
8	Sec. 3. A person who violates section 2 of this chapter commits
9	a Class C infraction. However, the violation is a Class B infraction
10	if the person has one (1) prior unrelated judgment for a violation
11	of section 2 of this chapter, and a Class A infraction if the person
12	has two (2) or more prior unrelated judgements for a violation of
13	section 2 of this chapter.
14	SECTION 11. IC 35-31.5-2-150.5 IS ADDED TO THE INDIANA
15	CODE AS A NEW SECTION TO READ AS FOLLOWS
16	[EFFECTIVE JULY 1, 2018]: Sec. 150.5. "Hashish", for purposes of
17	IC 35-48, has the meaning set forth in IC 35-48-1-16.8.
18	SECTION 12. IC 35-31.5-2-150.6 IS ADDED TO THE INDIANA
19	CODE AS A NEW SECTION TO READ AS FOLLOWS
20	[EFFECTIVE JULY 1, 2018]: Sec. 150.6. "Hash oil", for purposes
21	of IC 35-48, has the meaning set forth in IC 35-48-1-16.9.
22	SECTION 13. IC 35-31.5-2-316.9 IS REPEALED [EFFECTIVE
23	JULY 1, 2018]. Sec. 316.9. "Substance containing cannabidiol", for
24	purposes of IC 35-48, has the meaning set forth in IC 35-48-1-26.7.
25	SECTION 14. IC 35-31.5-2-358 IS ADDED TO THE INDIANA
26	CODE AS A NEW SECTION TO READ AS FOLLOWS
27	[EFFECTIVE JULY 1, 2018]: Sec. 358. "Zero THC hemp extract",
28	for purposes of IC 35-48, has the meaning set forth in
29	IC 35-48-1-28.
30	SECTION 15. IC 35-48-1-6.5 IS REPEALED [EFFECTIVE JULY
31	1, 2018]. Sec. 6.5. "Cannabidiol" has the meaning set forth in
32	IC 16-42-28.6-1.
33	SECTION 16. IC 35-48-3.5 IS ADDED TO THE INDIANA CODE
34	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
35	JULY 1, 2018]:
36	Chapter 3.5. Defenses Relating to Controlled Substances
37	Sec. 1. (a) This section does not apply to a person who sells
38	marijuana, hashish, hash oil, or tetrahydrocannabinol:
39	(1) without having obtained a certificate of analysis (as
40	defined in IC 24-4-21-1) showing that the controlled substance
41	contains no tetrahydrocannabinol; or
42	(2) after having obtained a certificate of analysis showing that



1	the controlled substance contains cannabinol.
2	(b) It is a defense to a prosecution under IC 35-48-4-2 (dealing
3	in a schedule I-III controlled substance), IC 35-48-4-7 (possession
4	of a controlled substance), IC 35-48-4-10 (dealing in marijuana,
5	hash oil, or hashish), or IC 35-48-4-11 (possession of marijuana,
6	hash oil, or hashish) that all of the following apply:
7	(1) The person is:
8	(A) a manufacturer of zero THC hemp extract as described
9	in IC 24-4-21; or
10	(B) an independent testing laboratory (as defined in
11	IC 24-4-21-1).
12	(2) The person is charged with an offense relating to
13	marijuana, hashish, hash oil, or tetrahydrocannabinol.
14	(3) The person possessed, delivered, or manufactured the
15	marijuana, hashish, hash oil, or tetrahydrocannabinol within
16	the scope of manufacturing or testing zero THC hemp extract
17	under IC 24-4-21.
18	(4) The person substantially complied with the requirements
19	of IC 24-4-21.
20	SECTION 17. IC 35-48-1-9 IS AMENDED TO READ AS
21	FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 9. "Controlled
22	substance" means a drug, substance, or immediate precursor in
23	schedule I, II, III, IV, or V under:
24	(1) IC 35-48-2-4, IC 35-48-2-6, IC 35-48-2-8, IC 35-48-2-10, or
25	IC 35-48-2-12, if IC 35-48-2-14 does not apply; or
26	(2) a rule adopted by the board, if IC 35-48-2-14 applies.
27	The term does not include zero THC hemp extract.
28	SECTION 18. IC 35-48-1-9.3 IS AMENDED TO READ AS
29	FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 9.3. (a) "Controlled
30	substance analog" means a substance:
31	(1) the chemical structure of which is substantially similar to that
32	of a controlled substance included in schedule I or II and that has;
33	or
34	(2) that a person represents or intends to have;
35	a narcotic, stimulant, depressant, or hallucinogenic effect on the central
36	nervous system substantially similar to or greater than the narcotic,
37	stimulant, depressant, or hallucinogenic effect on the central nervous
38	system of a controlled substance included in schedule I or II.
39	(b) The definition set forth in subsection (a) does not include:
40	(1) a controlled substance;
41	(2) a substance for which there is an approved new drug
42	application;



1	(3) a substance for which an exemption is in effect for
2	investigational use by a person under Section 505 of the federal
3	Food, Drug and Cosmetic Act (chapter 675, 52 Stat. 1052 (21
4	U.S.C. 355)), to the extent that conduct with respect to the
5	substance is permitted under the exemption; or
6	(4) a substance to the extent not intended for human consumption
7	before an exemption takes effect regarding the substance; or
8	(5) Zero THC hemp extract.
9	SECTION 19. IC 35-48-1-16.8 IS ADDED TO THE INDIANA
10	CODE AS A NEW SECTION TO READ AS FOLLOWS
11	[EFFECTIVE JULY 1, 2018]: Sec. 16.8. "Hashish" does not include
12	zero THC hemp extract.
13	SECTION 20. IC 35-48-1-16.9 IS ADDED TO THE INDIANA
14	CODE AS A NEW SECTION TO READ AS FOLLOWS
15	[EFFECTIVE JULY 1, 2018]: Sec. 16.9. "Hash oil" does not include
16	zero THC hemp extract.
17	SECTION 21. IC 35-48-1-19, AS AMENDED BY P.L.165-2014,
18	SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
19	JULY 1, 2018]: Sec. 19. (a) "Marijuana" means any part of the plant
20	genus Cannabis whether growing or not; the seeds thereof; the resin
21	extracted from any part of the plant, including hashish and hash oil; any
22	compound, manufacture, salt, derivative, mixture, or preparation of the
23	plant, its seeds or resin.
24	(b) The term does not include:
25	(1) the mature stalks of the plant;
26	(2) fiber produced from the stalks;
27	(3) oil or cake made from the seeds of the plant;
28	(4) any other compound, manufacture, salt, derivative, mixture,
29	or preparation of the mature stalks (except the resin extracted
30	therefrom);
31	(5) the sterilized seed of the plant which is incapable of
32	germination; or
33	(6) industrial hemp (as defined by IC 15-15-13-6); or
34	(7) zero THC hemp extract.
35	SECTION 22. IC 35-48-1-26.7 IS REPEALED [EFFECTIVE JULY
36	1, 2018]. Sec. 26.7. "Substance containing cannabidiol" has the
37	meaning set forth in IC 16-42-28.6-5.
38	SECTION 23. IC 35-48-1-28 IS ADDED TO THE INDIANA
39	CODE AS A NEW SECTION TO READ AS FOLLOWS
40	[EFFECTIVE JULY 1, 2018]: Sec. 28. "Zero THC hemp extract"
41	means a substance or compound that:
42	(1) is derived from or contains any part of the plant Cannabis



1	sativa L.;
2	(2) contains not more than three-tenths percent (0.3%) total
3	tetrahydrocannabinol (THC) by dry weight; and
4	(3) contains no other controlled substances.
5	SECTION 24. IC 35-48-4-8.5, AS AMENDED BY P.L.188-2017
6	SECTION 12, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
7	JULY 1, 2018]: Sec. 8.5. (a) A person who keeps for sale, offers for
8	sale, delivers, or finances the delivery of a raw material, an instrument
9	a device, or other object that is intended to be or that is designed or
10	marketed to be used primarily for:
11	(1) ingesting, inhaling, or otherwise introducing into the humar
12	body marijuana, hash oil, hashish, salvia, a synthetic drug, or a
13	controlled substance;
14	(2) testing the strength, effectiveness, or purity of marijuana, hash
15	oil, hashish, salvia, a synthetic drug, or a controlled substance;
16	(3) enhancing the effect of a controlled substance;
17	(4) manufacturing, compounding, converting, producing
18	processing, or preparing marijuana, hash oil, hashish, salvia, a
19	synthetic drug, or a controlled substance;
20	(5) diluting or adulterating marijuana, hash oil, hashish, salvia, a
21	synthetic drug, or a controlled substance by individuals; or
22	(6) any purpose announced or described by the seller that is in
23	violation of this chapter;
24	commits a Class A infraction for dealing in paraphernalia.
25	(b) A person who knowingly or intentionally violates subsection (a)
26	commits a Class A misdemeanor. However, the offense is a Level 6
27	felony if the person has a prior unrelated judgment or conviction under
28	this section.
29	(c) This section does not apply to the following:
30	(1) Items marketed for use in the preparation, compounding
31	packaging, labeling, or other use of marijuana, hash oil, hashish
32	salvia, a synthetic drug, or a controlled substance as an incident
33	to lawful research, teaching, or chemical analysis and not for sale
34	(2) Items marketed for or historically and customarily used in
35	connection with the planting, propagating, cultivating, growing
36	harvesting, manufacturing, compounding, converting, producing
37	processing, preparing, testing, analyzing, packaging, repackaging,
38	storing, containing, concealing, injecting, ingesting, or inhaling
39	of tobacco or any other lawful substance. excluding the lawful
40	possession of a substance containing cannabidiol under
41	IC 35-48-4-11.

(3) A qualified entity (as defined in IC 16-41-7.5-3) that provides



1	a syringe or needle as part of a program under IC 16-41-7.5.
2	(4) Any entity or person that provides funding to a qualified entity
3	(as defined in IC 16-41-7.5-3) to operate a program described in
4	IC 16-41-7.5.
5	SECTION 25. IC 35-48-4-11, AS AMENDED BY P.L.188-2017,
6	SECTION 13, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
7	JULY 1, 2018]: Sec. 11. (a) A person who:
8	(1) knowingly or intentionally possesses (pure or adulterated)
9	marijuana, hash oil, hashish, or salvia;
10	(2) knowingly or intentionally grows or cultivates marijuana; or
11	(3) knowing that marijuana is growing on the person's premises,
12	fails to destroy the marijuana plants;
13	commits possession of marijuana, hash oil, hashish, or salvia, a Class
14	B misdemeanor, except as provided in subsections (b) through (c).
15	(b) The offense described in subsection (a) is a Class A
16	misdemeanor if the person has a prior conviction for a drug offense.
17	(c) The offense described in subsection (a) is a Level 6 felony if:
18	(1) the person has a prior conviction for a drug offense; and
19	(2) the person possesses:
20	(A) at least thirty (30) grams of marijuana; or
21	(B) at least five (5) grams of hash oil, hashish, or salvia.
22	(d) It is a defense to a prosecution under subsection (a)(1) based on
21 22 23 24	the possession of a substance containing cannabidiol that:
24	(1) the person is a patient or caregiver registered under
25	IC 16-42-28.6 for the use of a substance containing cannabidiol;
26	(2) the person reasonably believed that the substance possessed
27	by the person was a substance containing cannabidiol; and
28	(3) the substance containing cannabidiol is packaged in a
29	container labeled with the origin, volume, and concentration by
30	weight of total THC, including its precursors and derivatives, and
31	cannabidiol.
32	(e) It is a defense to a prosecution under this section based on the
33	possession of a substance containing cannabidiol that:
34	(1) the substance containing cannabidiol has been approved by
35	the federal Food and Drug Administration or the federal Drug
36	Enforcement Agency as a prescription drug; and
37	(2) the substance was prescribed and dispensed in accordance
38	with the federal approval described in subdivision (1).



COMMITTEE REPORT

Madam President: The Senate Committee on Rules and Legislative Procedure, to which was referred Senate Bill No. 52, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Delete everything after the enacting clause and insert the following:

(SEE TEXT OF BILL)

and when so amended that said bill be reassigned to the Senate Committee on Corrections and Criminal Law.

(Reference is to 52 as introduced.)

LONG, Chairperson

COMMITTEE REPORT

Madam President: The Senate Committee on Corrections and Criminal Law, to which was referred Senate Bill No. 52, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Page 1, delete lines 1 through 11, begin a new paragraph and insert: "SECTION 1. IC 4-13-18-6, AS ADDED BY P.L.160-2006, SECTION 2, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 6. (a) A contractor's employee drug testing program must satisfy all of the following:

- (1) Each of the contractor's employees must be subject to a drug test at least one (1) time each year.
- (2) Subject to subdivision (1), the contractor's employees must be tested randomly. At least two percent (2%) of the contractor's employees must be randomly selected each month for testing.
- (3) The program must contain at least a five (5) drug panel that tests for the following:
 - (A) Amphetamines.
 - (B) Cocaine.
 - (C) Opiates (2000 ng/ml).
 - (D) PCP.
 - (E) THC.
- (4) The program must impose progressive discipline on an



employee who fails a drug test. The discipline must have at least the following progression:

- (A) After the first positive test, an employee must be:
 - (i) suspended from work for thirty (30) days;
 - (ii) directed to a program of treatment or rehabilitation; and
 - (iii) subject to unannounced drug testing for one (1) year, beginning the day the employee returns to work.
- (B) After a second positive test, an employee must be:
 - (i) suspended from work for ninety (90) days;
 - (ii) directed to a program of treatment or rehabilitation; and
 - (iii) subject to unannounced drug testing for one (1) year, beginning the day the employee returns to work.
- (C) After a third or subsequent positive test, an employee must be:
 - (i) suspended from work for one (1) year;
 - (ii) directed to a program of treatment or rehabilitation; and
 - (iii) subject to unannounced drug testing for one (1) year, beginning the day the employee returns to work.

The program may require dismissal of the employee after any positive drug test or other discipline more severe than is described in this subdivision.

- (b) An employer complies with the requirement of subsection (a) to direct an employee to a program of treatment or rehabilitation if the employer does either of the following:
 - (1) Advises the employee of any program of treatment or rehabilitation covered by insurance provided by the employer.
 - (2) If the employer does not provide insurance that covers drug treatment or rehabilitation programs, the employer advises the employee of agencies known to the employer that provide drug treatment or rehabilitation programs.
- (c) A positive result on a drug test due solely to an employee's use of zero THC hemp extract (as defined in IC 35-48-1-28) is not considered a positive test for purposes of this section.

SECTION 2. IC 16-18-2-45.5 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 45.5. "Cannabidiol", for purposes of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-1.

SECTION 3. IC 16-18-2-48.7 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 48.7. "Caregiver", for purposes of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-2.

SECTION 4. IC 16-18-2-272, AS AMENDED BY P.L.188-2017, SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 272. (a) "Patient", for purposes of IC 16-27-1, has



the meaning set forth in IC 16-27-1-6.

- (b) "Patient", for purposes of IC 16-28 and IC 16-29, means an individual who has been accepted and assured care by a health facility.
- (c) "Patient", for purposes of IC 16-36-1.5, has the meaning set forth in IC 16-36-1.5-3.
- (d) "Patient", for purposes of IC 16-39, means an individual who has received health care services from a provider for the examination, treatment, diagnosis, or prevention of a physical or mental condition.
- (e) "Patient", for purposes of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-3.

SECTION 5. IC 16-18-2-282, AS AMENDED BY P.L.188-2017, SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 282. (a) "Physician", except as provided in subsections (b) **and (c)**, through (d), means a licensed physician (as defined in section 202 of this chapter).

- (b) "Physician", for purposes of IC 16-41-12, has the meaning set forth in IC 16-41-12-7.
- (c) "Physician", for purposes of IC 16-37-1-3.1 and IC 16-37-3-5, means an individual who:
 - (1) was the physician last in attendance (as defined in section 282.2 of this chapter); or
 - (2) is licensed under IC 25-22.5.
- (d) "Physician", for purposes of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-4.
- (e) (d) "Physician", for purposes of IC 16-48-1, is subject to IC 16-48-1-2.

SECTION 6. IC 16-18-2-342.6 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 342.6. "Substance containing cannabidiol", for purposes of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-5.

SECTION 7. IC 16-18-2-354.7 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 354.7. "Treatment resistant epilepsy", for purposes of IC 16-42-28.6, has the meaning set forth in IC 16-42-28.6-6.

SECTION 8. IC 16-42-28.6 IS REPEALED [EFFECTIVE JULY 1, 2018]. (Drugs: Use of Cannabidiol for the Treatment of Epilepsy).".

Page 2, line 16, delete "is accredited:" and insert "that is accredited as a testing laboratory".

Page 2, line 17, delete "(i)".

Page 2, run in lines 16 through 17.

Page 2, line 21, delete "(ACLASS); or" and insert "(ACLASS).".

Page 2, delete lines 22 through 23.

Page 2, line 27, delete "extract;" and insert "extract for distribution in Indiana;".





Page 2, line 28, delete "an".

Page 2, line 29, delete "laboratory;" and insert "laboratory in Indiana;".

Page 2, line 41, delete "manufacturer shall:" and insert "manufacturer:".

Page 2, line 42, delete "destroy; or" and insert "may not distribute the batch; and".

Page 3, line 1, delete "reprocess;" and insert "may reprocess the batch to remove the tetrahydrocannabinol.".

Page 3, line 2, delete "the batch.".

Page 3, line 4, delete "testing." and insert "**testing in accordance** with section 3 of this chapter."

Page 3, line 6, delete "manufacture" and insert "manufacturer".

Page 4, between lines 22 and 23, begin a new paragraph and insert: "SECTION 13. IC 35-31.5-2-316.9 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 316.9. "Substance containing cannabidiol", for purposes of IC 35-48, has the meaning set forth in IC 35-48-1-26.7."

Page 4, between lines 27 and 28, begin a new paragraph and insert: "SECTION 14. IC 35-48-1-6.5 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 6.5. "Cannabidiol" has the meaning set forth in IC 16-42-28.6-1.".

Page 5, line 10, delete "while" and insert "within the scope of".

Page 6, between lines 29 and 30, begin a new paragraph and insert: "SECTION 21. IC 35-48-1-26.7 IS REPEALED [EFFECTIVE JULY 1, 2018]. Sec. 26.7. "Substance containing cannabidiol" has the meaning set forth in IC 16-42-28.6-5:".

Page 6, line 34, delete "genus".

Page 6, delete line 35 and insert "Cannabis sativa L.;".

Page 6, line 36, delete "no tetrahydrocannabinol;" and insert "not more than three-tenths percent (0.3%) total tetrahydrocannabinol (THC) by dry weight;".

Page 6, after line 37, begin a new paragraph and insert:

"SECTION 23. IC 35-48-4-8.5, AS AMENDED BY P.L.188-2017, SECTION 12, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 8.5. (a) A person who keeps for sale, offers for sale, delivers, or finances the delivery of a raw material, an instrument, a device, or other object that is intended to be or that is designed or marketed to be used primarily for:

- (1) ingesting, inhaling, or otherwise introducing into the human body marijuana, hash oil, hashish, salvia, a synthetic drug, or a controlled substance;
- (2) testing the strength, effectiveness, or purity of marijuana, hash



- oil, hashish, salvia, a synthetic drug, or a controlled substance;
- (3) enhancing the effect of a controlled substance;
- (4) manufacturing, compounding, converting, producing, processing, or preparing marijuana, hash oil, hashish, salvia, a synthetic drug, or a controlled substance;
- (5) diluting or adulterating marijuana, hash oil, hashish, salvia, a synthetic drug, or a controlled substance by individuals; or
- (6) any purpose announced or described by the seller that is in violation of this chapter;

commits a Class A infraction for dealing in paraphernalia.

- (b) A person who knowingly or intentionally violates subsection (a) commits a Class A misdemeanor. However, the offense is a Level 6 felony if the person has a prior unrelated judgment or conviction under this section.
 - (c) This section does not apply to the following:
 - (1) Items marketed for use in the preparation, compounding, packaging, labeling, or other use of marijuana, hash oil, hashish, salvia, a synthetic drug, or a controlled substance as an incident to lawful research, teaching, or chemical analysis and not for sale.
 - (2) Items marketed for or historically and customarily used in connection with the planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, or inhaling of tobacco or any other lawful substance. excluding the lawful possession of a substance containing cannabidiol under IC 35-48-4-11.
 - (3) A qualified entity (as defined in IC 16-41-7.5-3) that provides a syringe or needle as part of a program under IC 16-41-7.5.
 - (4) Any entity or person that provides funding to a qualified entity (as defined in IC 16-41-7.5-3) to operate a program described in IC 16-41-7.5.

SECTION 24. IC 35-48-4-11, AS AMENDED BY P.L.188-2017, SECTION 13, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2018]: Sec. 11. (a) A person who:

- (1) knowingly or intentionally possesses (pure or adulterated) marijuana, hash oil, hashish, or salvia;
- (2) knowingly or intentionally grows or cultivates marijuana; or
- (3) knowing that marijuana is growing on the person's premises, fails to destroy the marijuana plants;

commits possession of marijuana, hash oil, hashish, or salvia, a Class B misdemeanor, except as provided in subsections (b) through (c).



- (b) The offense described in subsection (a) is a Class A misdemeanor if the person has a prior conviction for a drug offense.
 - (c) The offense described in subsection (a) is a Level 6 felony if:
 - (1) the person has a prior conviction for a drug offense; and
 - (2) the person possesses:
 - (A) at least thirty (30) grams of marijuana; or
 - (B) at least five (5) grams of hash oil, hashish, or salvia.
- (d) It is a defense to a prosecution under subsection (a)(1) based on the possession of a substance containing cannabidiol that:
 - (1) the person is a patient or caregiver registered under IC 16-42-28.6 for the use of a substance containing cannabidiol;
 - (2) the person reasonably believed that the substance possessed by the person was a substance containing cannabidiol; and
 - (3) the substance containing cannabidiol is packaged in a container labeled with the origin, volume, and concentration by weight of total THC, including its precursors and derivatives, and cannabidiol.
- (e) It is a defense to a prosecution under this section based on the possession of a substance containing cannabidiol that:
 - (1) the substance containing cannabidiol has been approved by the federal Food and Drug Administration or the federal Drug Enforcement Agency as a prescription drug; and
 - (2) the substance was prescribed and dispensed in accordance with the federal approval described in subdivision (1).".

Renumber all SECTIONS consecutively.

and when so amended that said bill do pass.

(Reference is to SB 52 as printed January 11, 2018.)

YOUNG M, Chairperson

Committee Vote: Yeas 7, Nays 2.

